• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    2/27/24 12:31:10 PM ET
    $BIOR
    $CDXS
    $CLDI
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Chemicals
    Industrials
    Get the next $BIOR alert in real time by email

    Gainers

    • Janux Therapeutics (NASDAQ:JANX) stock increased by 189.9% to $43.78 during Tuesday's regular session. The company's market cap stands at $2.0 billion.
    • Viking Therapeutics (NASDAQ:VKTX) shares moved upwards by 91.96% to $73.87. The company's market cap stands at $7.4 billion.
    • CytomX Therapeutics (NASDAQ:CTMX) shares moved upwards by 41.81% to $2.34. The company's market cap stands at $156.7 million.
    • Biora Therapeutics (NASDAQ:BIOR) shares rose 33.24% to $1.4. The market value of their outstanding shares is at $38.0 million.
    • Codexis (NASDAQ:CDXS) shares increased by 31.4% to $4.21. The company's market cap stands at $293.6 million.
    • Hims & Hers Health (NYSE:HIMS) shares moved upwards by 31.02% to $13.43. The company's market cap stands at $2.8 billion. As per the news, the Q4 earnings report came out yesterday.

    Losers

    • Minerva Neurosciences (NASDAQ:NERV) stock decreased by 57.1% to $2.92 during Tuesday's regular session. The market value of their outstanding shares is at $20.4 million. As per the news, the Q4 earnings report came out 3 days ago.
    • NRX Pharmaceuticals (NASDAQ:NRXP) stock declined by 32.77% to $0.29. The company's market cap stands at $24.4 million.
    • Calidi Biotherapeutics (AMEX:CLDI) shares decreased by 24.93% to $0.91. The market value of their outstanding shares is at $32.2 million.
    • Telesis Bio (NASDAQ:TBIO) stock fell 21.22% to $0.52. The company's market cap stands at $15.5 million.
    • Qualigen Therapeutics (NASDAQ:QLGN) shares decreased by 15.21% to $0.49. The company's market cap stands at $2.5 million.
    • SI-BONE (NASDAQ:SIBN) stock decreased by 14.15% to $17.64. The market value of their outstanding shares is at $714.2 million. The company's, Q4 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BIOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIOR
    $CDXS
    $CLDI
    $CTMX

    CompanyDatePrice TargetRatingAnalyst
    CytomX Therapeutics Inc.
    $CTMX
    3/16/2026$12.00Neutral → Overweight
    Analyst
    Hims & Hers Health Inc.
    $HIMS
    3/10/2026$24.00Sell → Neutral
    Citigroup
    Hims & Hers Health Inc.
    $HIMS
    3/10/2026$23.00Underperform → Neutral
    BofA Securities
    Hims & Hers Health Inc.
    $HIMS
    3/9/2026$30.00Hold → Buy
    Needham
    Hims & Hers Health Inc.
    $HIMS
    2/24/2026Buy → Neutral
    BTIG Research
    SI-BONE Inc.
    $SIBN
    1/27/2026$21.00Buy
    TD Cowen
    CytomX Therapeutics Inc.
    $CTMX
    1/20/2026$10.00Buy
    Guggenheim
    Hims & Hers Health Inc.
    $HIMS
    1/12/2026$33.00In-line
    Evercore ISI
    More analyst ratings

    $BIOR
    $CDXS
    $CLDI
    $CTMX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026

    WILMINGTON, Del., March 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a conference call at 8:00am ET on Tuesday, March 24, 2026. In addition to reviewing the Company's financial results for the fiscal year ended December 31, 2025, the Company will provide an update on the significant progress achieved across its drug development programs and the HOPE Therapeutics clinical network, milestones that bring the Company closer to its founding mission of preventing suicide and transforming the treatment of depression and PTSD to improve the lives of patient

    3/19/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

    SOUTH SAN FRANCISCO, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the pricing of an underwritten public offering of 45,990,567 shares of its common stock at a price to the public of $5.30 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,179,245 shares of common stock. The gross proceeds to CytomX from the offering are expected to be $250 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, CytomX granted the underwriters a 30-day option to purchase up to an additiona

    3/17/26 10:46:40 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx's Preservative-Free Ketamine Application

    Determination of bioequivalence to the Reference Listed Drug is essential for approval of an Abbreviated New Drug Application (ANDA).FDA has advised NRx in written correspondence that it has not identified any bioequivalence deficiencies in the Company's Preservative-Free Ketamine product. This communication is deemed preliminary until final supervisory review.NRx continues to anticipate an FDA GDUFA decision on its ANDA application in Summer 2026 as previously announced.The ANDA process is focused on offering a preservative-free alternative in the existing ketamine market through the FDA Office of Generic Drugs and is separate from NRx's path to a New Drug Application to use ketamine in the

    3/17/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOR
    $CDXS
    $CLDI
    $CTMX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Becklund Irene

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    3/18/26 4:17:47 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Chi Michael

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    3/18/26 4:17:34 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Boughton Soleil

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    3/18/26 4:17:40 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $BIOR
    $CDXS
    $CLDI
    $CTMX
    SEC Filings

    View All

    SEC Form 424B5 filed by CytomX Therapeutics Inc.

    424B5 - CytomX Therapeutics, Inc. (0001501989) (Filer)

    3/18/26 4:05:53 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by CytomX Therapeutics Inc.

    424B5 - CytomX Therapeutics, Inc. (0001501989) (Filer)

    3/16/26 4:37:02 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3ASR filed by CytomX Therapeutics Inc.

    S-3ASR - CytomX Therapeutics, Inc. (0001501989) (Filer)

    3/16/26 4:01:39 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOR
    $CDXS
    $CLDI
    $CTMX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CytomX Therapeutics upgraded by Analyst with a new price target

    Analyst upgraded CytomX Therapeutics from Neutral to Overweight and set a new price target of $12.00

    3/16/26 11:34:14 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hims & Hers Health upgraded by Citigroup with a new price target

    Citigroup upgraded Hims & Hers Health from Sell to Neutral and set a new price target of $24.00

    3/10/26 8:37:35 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health upgraded by BofA Securities with a new price target

    BofA Securities upgraded Hims & Hers Health from Underperform to Neutral and set a new price target of $23.00

    3/10/26 8:37:14 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $BIOR
    $CDXS
    $CLDI
    $CTMX
    Leadership Updates

    Live Leadership Updates

    View All

    Hims & Hers Names Kathryn Beiser as Chief Communications Officer

    The global communications leader, who previously held roles at Eli Lilly and Kaiser Permanente, joins the world's leading consumer health platform in its next phase of growth Hims & Hers Health, Inc. (NYSE:HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Officer. In this role, Beiser will lead external and internal communications for the company as it enters a new phase of domestic and international growth. In her role as CCO, Beiser will report to CEO Andrew Dudum and focus on continuing to build the Hims & Hers brand and reputation while helping the industry understand the company's expansive vision for the

    3/10/26 8:08:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer

    Prof. Brown is a pioneer in Transcranial Magnetic Stimulation (TMS) and serves as current President of the Clinical TMS Society and Editor-in-Chief of the Transcranial Magnetic Stimulation journal.Extensive publication history in the science of neuroplasticity and its relationship to healing depression and PTSD.Unique background in charting a path for forward deployment of TMS with neuroplastic medication to treat depression and PTSD in military personnel, veterans, and first responders. WILMINGTON, Del., March 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, today announced that it has appointed Prof. Joshua C. Brown, MD, P

    3/2/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

    Continued clinical execution across TRACTr programs JANX007 and JANX008 JANX007 enrolling in Phase 1b Taxane-naïve patient population in metastatic castration-resistant prostate cancer (mCRPC) JANX008 enrolling expansion cohorts in defined tumor settings Initiated Phase 1 study of JANX011 in healthy volunteers Entered collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic for solid tumors Appointment of William Go, M.D., Ph.D., as Chief Medical Officer Strong year-end cash position supporting continued pipeline execution Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharma

    2/26/26 4:01:00 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOR
    $CDXS
    $CLDI
    $CTMX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Jackson Andrew C. bought $5,000 worth of shares (2,500 units at $2.00) (SEC Form 4)

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    8/25/25 8:47:36 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Poma Eric E bought $50,000 worth of shares (25,000 units at $2.00) (SEC Form 4)

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    8/25/25 8:47:39 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Leftwich Scott bought $250,000 worth of shares (125,000 units at $2.00), increasing direct ownership by 2,212% to 130,650 units (SEC Form 4)

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    8/25/25 8:47:37 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIOR
    $CDXS
    $CLDI
    $CTMX
    Financials

    Live finance-specific insights

    View All

    NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026

    WILMINGTON, Del., March 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a conference call at 8:00am ET on Tuesday, March 24, 2026. In addition to reviewing the Company's financial results for the fiscal year ended December 31, 2025, the Company will provide an update on the significant progress achieved across its drug development programs and the HOPE Therapeutics clinical network, milestones that bring the Company closer to its founding mission of preventing suicide and transforming the treatment of depression and PTSD to improve the lives of patient

    3/19/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update

    - Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan ("Varseta-M") EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted for mid-year with goal to align on potential Varseta-M registrational trial design in late line CRC - - Varseta-M Phase 1 study evaluating combination with bevacizumab initiated; Phase 1b/2 chemotherapy combination study to be initiated by the end of 2026 - - Initial CX-801 PROBODY Interferon-alpha-2b Phase 1 combination data with KEYTRUDA® (pembrolizumab) in melanoma expected by the end of 2026 - - Company to host conference call today at 8 a.m. ET / 5 a.m. PT - SOUTH SAN FRANCISCO, Calif., M

    3/16/26 7:05:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CytomX's Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer

    - Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - - Grade 3 diarrhea rate of 10% in ongoing dose optimization cohorts - - FDA interactions targeted for mid-year with goal to align on potential registrational trial design in late-line colorectal cancer (CRC) - - Phase 1 study evaluating combination with bevacizumab initiated; Phase 1b/2 chemotherapy combination study to be initiated by the end of 2026 - - Conference call on Monday, March 16 at 8:00 a.m. ET - SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics

    3/16/26 7:00:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOR
    $CDXS
    $CLDI
    $CTMX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SI-BONE Inc.

    SC 13G/A - SI-BONE, Inc. (0001459839) (Subject)

    11/14/24 6:27:27 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by SI-BONE Inc.

    SC 13G - SI-BONE, Inc. (0001459839) (Subject)

    11/14/24 4:43:38 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

    SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    11/14/24 4:30:54 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care